Point72 Asia Singapore Pte. Ltd. Invests $42,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 5,427 shares of the company’s stock, valued at approximately $42,000.

Other hedge funds also recently bought and sold shares of the company. Empowered Funds LLC boosted its holdings in shares of iTeos Therapeutics by 5.0% during the 4th quarter. Empowered Funds LLC now owns 69,072 shares of the company’s stock worth $530,000 after purchasing an additional 3,305 shares during the last quarter. Virtu Financial LLC lifted its position in iTeos Therapeutics by 84.3% during the fourth quarter. Virtu Financial LLC now owns 18,493 shares of the company’s stock worth $142,000 after buying an additional 8,460 shares in the last quarter. US Bancorp DE lifted its position in iTeos Therapeutics by 40.1% during the fourth quarter. US Bancorp DE now owns 16,919 shares of the company’s stock worth $130,000 after buying an additional 4,843 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in iTeos Therapeutics during the fourth quarter worth $142,000. Finally, Raymond James Financial Inc. acquired a new position in iTeos Therapeutics during the fourth quarter worth $1,159,000. Institutional investors and hedge funds own 97.16% of the company’s stock.

Insider Activity at iTeos Therapeutics

In other news, major shareholder Ansbert Gadicke sold 1,031,931 shares of the stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the sale, the insider now owns 3,452,797 shares of the company’s stock, valued at approximately $27,829,543.82. This represents a 23.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the firm’s stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $5,079,339.46. Following the completion of the transaction, the insider now directly owns 2,108,594 shares of the company’s stock, valued at approximately $16,995,267.64. The trade was a 23.01% decrease in their position. The disclosure for this sale can be found here. 12.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ITOS has been the subject of a number of recent research reports. JPMorgan Chase & Co. downgraded iTeos Therapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $15.00 to $8.00 in a research note on Tuesday, May 13th. Wells Fargo & Company restated an “overweight” rating and set a $13.00 price objective (down from $16.00) on shares of iTeos Therapeutics in a research report on Wednesday. Wedbush reiterated an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Raymond James set a $12.00 price target on shares of iTeos Therapeutics in a report on Wednesday. Finally, HC Wainwright lowered shares of iTeos Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, May 14th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, iTeos Therapeutics presently has an average rating of “Hold” and a consensus target price of $17.86.

iTeos Therapeutics Price Performance

NASDAQ ITOS opened at $7.81 on Monday. The stock has a market capitalization of $298.92 million, a P/E ratio of -2.48 and a beta of 1.39. The firm’s 50-day moving average is $6.61 and its two-hundred day moving average is $7.40. iTeos Therapeutics, Inc. has a 12 month low of $4.80 and a 12 month high of $18.70.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.14. As a group, analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 EPS for the current year.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.